NCT00048503View on ClinicalTrials.gov

Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older

PHASE2CompletedINTERVENTIONAL
Enrollment

88

Participants

Timeline

Start Date

June 30, 2002

Study Completion Date

November 30, 2005

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

ZARNESTRA, tipifarnib, R115777

All Listed Sponsors
lead

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

INDUSTRY

NCT00048503 - Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older | Biotech Hunter | Biotech Hunter